Select Publications
Click title to access publication
Antidopaminergic Medications in Huntington’s Disease
Tan AM, Geva M, Goldberg YP, et al. Antidopaminergic medications in Huntington’s disease. Journal of Huntington’s Disease. 2025;0(0). doi:10.1177/18796397241304312
Pridopidine does not significantly prolong the QTc interval at the clinically relevant therapeutic dose
Darpo B, Geva M, Ferber G, et al. Neurol Ther. 2023;12(2)597-617. doi:10.1007/s40120-023-00449-w
Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine
Wang SM, Wu HE, Yasui Y, et al. Autophagy. 2023;19(1):126-151. doi:10.1080/15548627.2022.2063003
Pridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model
Lenoir S, Lahaye RA, Vitet H, et al. Neurobiol Dis. 2022;173:10585. doi:10.1016/j.nbd.2022.105857
Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma
Geva M, Gershoni-Emek N, Naia L, et al. Sci Rep. 2021;11(1):21975. doi:10.1038/s41598-021-01077-w
Pridopidine reduces mutant huntingtin-induced endoplasmic reticulum stress by modulation of the sigma-1 receptor
Shenkman M, Geva M, Gershoni-Emek N, et al. J Neurochem. 2021;158(2):467-481. doi:10.1111/jnc.1536
Sigma-1 receptor (S1R) interaction with cholesterol: mechanisms of S1R activation and its role in neurodegenerative diseases
Zhemkov V, Geva M, Hayden MR, Bezprozvanny I. Int J Mol Sci. 2021;22(8):4082. doi:10.3390/ijms22084082
The sigma-1 receptor mediates pridopidine rescue of mitochondrial function in Huntington disease models
Naia L, Ly P, Mota SI, et al. Neurotherapeutics. 2021;18(2):1017-1038. doi:10.1007/s13311-021-01022-9
Effects of pridopidine on functional capacity in early-stage participants from the PRIDE-HD study
McGarry A, Leinonen M, Kieburtz K, Geva M, Olanow CW, Hayden M. J Huntingtons Dis. 2020;9(4):371-380. doi:10.3233/JHD-200440
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study
Grachev ID, Meyer PM, Becker GA, et al. Eur J Nucl Med Mol Imaging. 2021;48(4):1103-1115. doi:10.1007/s00259-020-05030-3
Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease
McGarry A, Auinger P, Kieburtz K, et al. J Huntingtons Dis. 2020;9(2):173-184. doi:10.3233/JHD-190393
Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor
Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA. Neurobiol Dis. 2019;129:118-129. doi:10.1016/j.nbd.2019.05.009
Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques
Johnston TH, Geva M, Steiner L, et al. Mov Disord. 2019;34(5):708-716. doi:10.1002/mds.27565
Impairment and restoration of homeostatic plasticity in cultured cortical neurons from a mouse model of Huntington disease
Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA. Front Cell Neurosci. 2019;13:209. doi:10.3389/fncel.2019.00209
Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model
Ionescu A, Gradus T, Altman T, et al. Cell Death Dis. 2019;10(3):210. doi:10.1038/s41419-019-1451-2
Pridopidine induces functional neurorestoration via the sigma-1 receptor in a mouse model of Parkinson’s disease
Francardo V, Geva M, Bez F, et al. Neurotherapeutics. 2019;16(2):465-479. doi:10.1007/s13311-018-00699-9
Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Reilmann R, McGarry A, Grachev ID, et al; European Huntington’s Disease Network; Huntington Study Group investigators.. Lancet Neurol. 2019;18(2):165-176. doi:10.1016/S1474-4422(18)30391-0
Pridopidine stabilizes mushroom spines in mouse models of Alzheimer’s disease by acting on the sigma-1 receptor
Ryskamp D, Wu L, Wu J, et al. Neurobiol Dis. 2019;124:489-504. doi:10.1016/j.nbd.2018.12.022
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
Kusko R, Dreymann J, Ross J, et al. Mol Neurodegener. 2018;13(1):25. doi:10.1186/s13024-018-0259-3
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice
Garcia-Miralles M, Geva M, Tan JY, et al. JCI Insight. 2017;2(23):e95665. doi:10.1172/jci.insight.95665
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease
Ryskamp D, Wu J, Geva M, et al. Neurobiol Dis. 2017;97(pt A):46-59. doi:10.1016/j.nbd.2016.10.006
Pridopidine activates neuroprotective pathways impaired in Huntington Disease
Geva M, Kusko R, Soares H, et al. Hum Mol Genet. 2016;25(18):3975-3987. doi:10.1093/hmg/ddw2
Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
Garcia J, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker R, Saft C, Magnet M, Sword A, Rembratt A, Tedroff J, MermaiHD study investigators. Lancet Neurology. 2011; Dec;10(12):1049-57. doi: 10.1016/S1474-4422(11)70233-2